ARDS - Aridis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 6.66M
Enterprise value 7.91M
Trailing P/E 2.83
Forward P/E 1.61
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.40
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.27

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-61.54%
S&P500 52-week change 30.07%
52-week high 32.7700
52-week low 30.1500
50-day moving average 30.2436
200-day moving average 30.8322

Share statistics

Avg vol (3-month) 33.74M
Avg vol (10-day) 318.12M
Shares outstanding 536.08M
Implied shares outstanding 6N/A
Float 827.48M
% held by insiders 131.53%
% held by institutions 111.60%
Shares short (14 May 2023) 4756.18k
Short ratio (14 May 2023) 42.35
Short % of float (14 May 2023) 42.18%
Short % of shares outstanding (14 May 2023) 42.10%
Shares short (prior month 13 Apr 2023) 4573.28k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin 0.00%
Operating margin (ttm)-970.33%

Management effectiveness

Return on assets (ttm)-90.36%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)3.09M
Revenue per share (ttm)0.17
Quarterly revenue growth (yoy)22.90%
Gross profit (ttm)-22.61M
EBITDA -29.51M
Net income avi to common (ttm)-30.37M
Diluted EPS (ttm)-1.8300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.88M
Total cash per share (mrq)0.14
Total debt (mrq)6.13M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.31
Book value per share (mrq)-0.90

Cash flow statement

Operating cash flow (ttm)-29.13M
Levered free cash flow (ttm)-19.47M